Metabolism and elimination of quinine in healthy volunteers
- 12 August 2003
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 59 (5-6), 423-427
- https://doi.org/10.1007/s00228-003-0637-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)Clinical Pharmacology & Therapeutics, 2002
- Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 2001
- Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450Xenobiotica, 2000
- Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*Clinical Pharmacology & Therapeutics, 1997
- Evidence for involvement of human CYP3A in the 3‐hydroxylation of quinineBritish Journal of Clinical Pharmacology, 1997
- Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetineEuropean Journal of Clinical Pharmacology, 1996
- Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.1995
- Fluvoxamine is a potent inhibitor of cytochrome P4501A2Biochemical Pharmacology, 1993
- The reproducibility of quinine bioavailability.British Journal of Clinical Pharmacology, 1993
- Identification of new urinary metabolites in man of quinine using methane chemical ionization gas chromatography-mass spectrometryXenobiotica, 1981